Granules India Ltd - Company Profile
Powered by 
All the sales intelligence you need on Granules India Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Granules India Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Granules India Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Granules India Ltd. (Granules) is a vertically integrated pharmaceutical company that specialises in the development, manufacturing, and distribution of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company's core products include Ibuprofen, Metformin, Paracetamol, Methocarbamol, and Guaifenesin. Granules also operates a consumer health division, Granules Consumer Health (GCH), which focuses on large-volume pharmaceutical products. The company's products are used by a diverse range of customers, including leading generic and branded pharmaceutical companies, in both regulated and semi-regulated markets. Its target markets include the US, Canada and India, among others. Granules is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad, Telangana, 500084
Website
www.granulesindia.com
Telephone
91 40 69043500
No of Employees
4,066
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRANULES (NSE)
Revenue (2025)
$535.6M
-0.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
23.7%
(2025 vs 2024)
Market Cap*
$2.0B
Net Profit Margin (2025)
XYZ
24.5%
(2025 vs 2024)
* As of and is in US$
Granules India Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Caplets | Customized Packaging | COLCRYS |
| Capsules | Contract Manufacturing Services | Allegra |
| Tablets | Neurontin | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Others | In April, Granules Life Sciences Private Limited received the Establishment Inspection Report from the US Food and Drug Administration at its manufacturing facility in Shamirpet, Telangana, India. |
| 2026 | Regulatory Approval | In January, Granules Pharmaceuticals secured the US Food and Drug Administration's tentative approval for Amphetamine Extended-Release Tablets with 180-day exclusivity. |
| 2025 | Corporate Changes/Expansions | In December, the company opened the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering at the Technology Research Park of IIT Hyderabad. |
Competitor Comparison
| Key Parameters | Granules India Ltd | Mankind Pharma Ltd | Divi's Laboratories Ltd | Hikal Ltd | Concord Biotech Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | New Delhi | Hyderabad | Mumbai | Ahmedabad |
| State/Province | Telangana | Delhi | Telangana | Maharashtra | Gujarat |
| No. of Employees | 4,066 | 27,000 | 18,300 | 2,062 | 1,571 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Krishna Prasad Chigurupati | Chairman; Managing Director | Executive Board | 2019 | 70 |
| Mukesh Surana | Chief Financial Officer | Senior Management | 2022 | - |
| PV Srinivas | Chief Technology Officer | Senior Management | - | - |
| Tushar Zade | Chief Transformation Officer | Senior Management | 2026 | - |
| Vinodkumar Parur | Chief Human Resources Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer